NCT06181344 Implementation and Evaluation of a Fear of Cancer Recurrence Screening, Referral and Management Program
| NCT ID | NCT06181344 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Fear of Cancer Recurrence |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,980 participants |
| Start Date | 2024-07-26 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,980 participants in total. It began in 2024-07-26 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the process and outcomes of an implementation program designed to implement fear of cancer screening, referral and management into routine cancer care clinics, using a stepped-wedge cluster randomized controlled trial.
Eligibility Criteria
Inclusion Criteria: * All patients diagnosed with non-metastatic breast, gynecological, or colorectal cancer, and who have completed primary and adjuvant treatment within the past two years will be eligible for the proposed screening program. Exclusion Criteria: * All cancer patients beyond two years post-treatment; and diagnosed with metastatic cancer or non-breast, non-gynecological, and non-colorectal cancer.
Contact & Investigator
Danielle Ng, PhD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT06181344 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fear of Cancer Recurrence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06181344 currently recruiting?
Yes, NCT06181344 is actively recruiting participants. Contact the research team at dwlng@hku.hk for enrollment information.
Where is the NCT06181344 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong.
Who is sponsoring the NCT06181344 clinical trial?
NCT06181344 is sponsored by The University of Hong Kong. The principal investigator is Danielle Ng, PhD at The University of Hong Kong. The trial plans to enroll 1,980 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.